A gamma secretase modulator developed by Research Consortium members Rudy Tanzi, Ph.D., of Massachusetts and Steve Wagner, Ph.D., of UCSD, with funding from Cure Alzheimer's Fund has proven to be so promising that it received a Blueprint grant from the NIH that will now carry it through the first phases of clinical testing. By modulating, but not eradicating, the activity of gamma secretase, the molecule interferes with the production of amyloid beta 42, a cornerstone of Alzheimer's pathology.